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Abstract Influenza viruses undergo continual antigenic evolution allowing mutant viruses to 
evade host immunity acquired to previous virus strains. Antigenic phenotype is often assessed 
through pairwise measurement of cross-reactivity between influenza strains using the 
hemagglutination inhibition (HI) assay. Here, we extend previous approaches to antigenic 
cartography, and simultaneously characterize antigenic and genetic evolution by modeling the 
diffusion of antigenic phenotype over a shared virus phylogeny. Using HI data from influenza 
lineages A/H3N2, A/H1N1, B/Victoria and B/Yamagata, we determine patterns of antigenic drift 
across viral lineages, showing that A/H3N2 evolves faster and in a more punctuated fashion than 
other influenza lineages. We also show that year-to-year antigenic drift appears to drive incidence 
patterns within each influenza lineage. This work makes possible substantial future advances in 
investigating the dynamics of influenza and other antigenically-variable pathogens by providing a 
model that intimately combines molecular and antigenic evolution.
DOI: 10.7554/eLife.01914.001
Introduction
Seasonal influenza infects between 10% and 20% of the human population every year, causing an 
estimated 250,000 to 500,000 deaths annually (Influenza Fact sheet, 2009). Although individuals 
develop long-lasting immunity to particular influenza strains after infection, antigenic mutations to the 
influenza virus genome result in proteins that are recognized to a lesser degree by the human immune 
system, leaving individuals susceptible to future infection. The influenza virus population continually 
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evolves in antigenic phenotype in a process known as antigenic drift. A large proportion of the disease 
burden of influenza stems from antigenic drift, which allows individuals to be infected multiple times 
throughout their lives. Although influenza vaccines may lack efficacy for a variety of reasons (Osterholm 
et al., 2012), antigenic drift causes efficacy of a fixed vaccine formulation against circulating viruses to 
decline over time. A thorough understanding of the process of antigenic drift is essential to public 
health efforts to control mortality and morbidity through the use of a seasonal influenza vaccine.
Before 2009, there were four major lineages of influenza circulating within the human population: 
the H3N2 and H1N1 subtypes of influenza A, and the Victoria and Yamagata lineages of influenza B. In 
the case of influenza A, subtypes A/H3N2 and A/H1N1 refer to the genes, hemagglutinin (H or HA) 
and neuraminidase (N or NA), that are primarily responsible for the antigenic character of a strain. In 
the case of influenza B, Victoria (B/Vic) and Yamagata (B/Yam) refer to antigenically distinct lineages 
which diverged from a single lineage prior to 1980 (Rota et al., 1990). Mutations to the HA1 region 
of the hemagglutinin protein are thought to drive the majority of antigenic drift in the influenza virus 
(Wiley et al., 1981; Nelson and Holmes, 2007). Experimental characterization of antigenic phenotype 
is possible through the hemagglutination inhibition (HI) assay (Hirst, 1943), which measures the cross-
reactivity of one virus strain to serum raised against another strain through challenge or vaccination. 
Sera raised against older strains react poorly to more recent viruses resulting in new strains having a 
selective advantage over previously established strains.
The results of many HI assays across a multitude of viruses of a single subtype can be combined to 
yield a two-dimensional map, quantifying antigenic similarity and distance (Smith et al., 2004). The 
antigenic map of influenza A/H3N2 has shown substantial evolution of the influenza virus population 
since its emergence in 1968. Evolution of antigenic phenotype appears punctuated with episodes of 
more rapid innovation interspersed by periods of relative stasis, whereas genetic evolution appears 
more continuous (Smith et al., 2004), suggesting that a relatively small number of genetic changes or 
combinations of genetic changes may drive changes in antigenic phenotype (Koel et al., 2013). The 
process of antigenic drift results in the rapid turnover of the virus population, so that despite mutation, 
genetic diversity among contemporaneous viruses remains low. Such population turnover is supported 
by phylogenetic analysis that shows a characteristically ‘spindly’ tree with a single predominant trunk 
lineage and transitory side branches that persist for only 1–5 years (Fitch et al., 1997).
eLife digest Every year, seasonal influenza, commonly called flu, infects up to one in five people 
around the world, and causes up to half a million deaths. Even though the human immune system 
can detect and destroy the virus that causes influenza, people can catch flu many times throughout 
their lifetimes because the virus keeps evolving in an effort to avoid the immune system. This 
antigenic drift—so-called because the antigens displayed by the virus keep changing—also explains 
why influenza vaccines become less effective over time and need to be reformulated every year.
It is possible to determine which antigens are displayed by a new strain of the virus by observing 
how blood samples that respond to known strains respond to the new strain. This information about 
the “antigenic phenotype” of the virus can be plotted on an antigenic map in which strains with 
similar antigens cluster together. Gene sequencing has shown that there are four subtypes of the flu 
virus that commonly infect people; but the relationship between changes in antigenic phenotype and 
changes in gene sequences of the influenza virus is poorly understood.
Bedford et al. have now developed an approach to combine antigenic maps with genetic 
information about the four subtypes of the human flu virus. This revealed that the antigenic 
phenotype of H3N2—a subtype that is becoming increasingly common—evolved faster than the 
other three subtypes. Further, a correlation was observed between antigenic drift and the number 
of new influenza cases per year for each flu strain. This suggests that knowing which antigenic 
phenotypes are present at the start of flu season could help predict which strains of the virus will 
predominate later on.
The work of Bedford et al. provides a useful framework to study influenza, and could help to 
pinpoint which changes in viral genes cause the changes in antigens. This information could 
potentially speed up the development of new flu vaccines for each flu season.
DOI: 10.7554/eLife.01914.002
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Previously, the antigenic and genetic patterns of influenza evolution have been analyzed essentially 
in isolation. An antigenic map is constructed from a panel of HI measurements, and a phylogenetic 
tree is constructed from sequence data. However, the opportunity for a combined approach exists as 
both the antigenic map and the phylogenetic tree often contain many of the same isolates. Here, we 
implement a flexible Bayesian approach to jointly characterize the antigenic and genetic evolution 
of the influenza virus population. We apply this approach to investigate the dynamics of A/H3N2, 
A/H1N1, B/Vic and B/Yam viruses, and, for the first time, present detailed reconstructions of the anti-
genic dynamics of all four circulating influenza lineages.
Results and discussion
Antigenic and evolutionary cartography
To assess patterns of antigenic evolution among influenza strains, we implemented a Bayesian 
probabilistic analog of multidimensional scaling (MDS), referred to here as BMDS (see ‘Materials and 
methods’). In this model, viruses and sera are given N-dimensional locations, thus specifying an ‘anti-
genic map’, such that distances between viruses and sera in this space are inversely proportional to 
cross-reactivity. In the BMDS model, a map distance of one antigenic unit translates to an expectation 
of a twofold drop in HI titer between virus and sera. Maps that produce pairwise distances most 
congruent with the observed titers will have a high likelihood and will be favored by the BMDS model. 
We integrate over sources of uncertainty, such as antigenic locations, in a flexible Bayesian fashion. 
We apply this model to HI measurements of virus isolates against post-infection ferret antisera for 
influenza A/H3N2, A/H1N1, B/Vic and B/Yam.
We begin with Bayesian analogs of the models used by Smith et al. (2004), in which viruses and sera 
are represented as N-dimensional locations as described in the ‘Antigenic cartography’ section of ‘Materials 
and methods’. In this case, ‘serum potencies’ are fixed to the maximum titers exhibited by particular ferret 
sera and give the baseline expectation for titer when virus and serum are antigenically identical. Potency 
differs between serum isolates due to experimental noise (e.g., variation in serum concentration), but also 
due to differential ferret immune responses, causing some serum isolates to inhibit hemagglutination at 
generally higher titers than other isolates. In this model, virus and serum locations follow an uninformative 
diffuse normal prior. After comparing models of differing dimensions, Smith et al. (2004) arrive at a 2D 
model as the preferred model for their data. Smith et al. (2004) implement a form of MDS, seeking to 
optimize virus and serum locations such that the sum of squared errors between expected and observed 
titers is minimized (Equation 3 of ‘Materials and methods’). Here, in implementing BMDS, we provide a 
likelihood function for the probability of observing HI data given virus and serum locations (Equation 8 of 
‘Materials and methods’) and seek to estimate model parameters through Bayesian inference using Markov 
Chain Monte Carlo (MCMC). However, the basic antigenic model describing drop in HI titer as proportional 
to Euclidean distance between virus and serum locations is identical between these methods.
We test model performance by constructing training datasets representing 90% of the HI measure-
ments for each of the four influenza lineages and test datasets representing the remaining 10% of the 
measurements for each lineage. By fitting the BMDS model to the training dataset, we are able to 
predict HI titers in the test dataset and compare these predicted titers to observed titers. We find that 
a two-dimensional model has better predictive power than models of lower or higher dimension in all 
four influenza lineages (models 1–5; Table 1). We find that this 2D model performs well, yielding an 
average absolute predictive error of between 0.78 and 0.91 log2 HI titers across influenza lineages (model 
2; Table 1), in line with the results of Smith et al. (2004). Consequently, we specify a two-dimensional 
model in all subsequent analyses. The finding of a low-dimensional map across influenza lineages 
extends previous studies in A/H3N2 (Smith et al., 2004) and remains an interesting and fundamental 
empirical observation.
Previous work on influenza antigenic and genetic evolution has shown that antigenic distance 
accumulates with increasing genetic distance (Hay and Gregory, 2001; Smith et al., 2004; Russell 
et al., 2008). Here, we examine pairwise relationships between viruses and observe a correlation 
between amino acid mutations and antigenic distance (Figure 1) and a similar correlation between 
phylogenetic distance, measured in years, and antigenic distance (Figure 1). Thus, genetic relationships 
between viruses provide some predictive power to estimate antigenic distances in the absence of HI 
data. However, the magnitudes of the coefficients of determination R2are low (Figure 1), suggesting 
that genetic relationships alone will not completely resolve antigenic distances.
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Consequently, we seek to flexibly incorporate genetic data by modeling antigenic phenotype as an 
evolutionary diffusion (Lemey et al., 2010), wherein a virus’s antigenic character state evolves along 
branches of the phylogenetic tree according to a Brownian motion process (see ‘Materials and methods’). 
The phylogenetic diffusion process acts as a prior on virus locations, so that genetically similar viruses 
are expected to share similar antigenic locations. The antigenic diffusion process includes both systematic 
drift with time and covariance induced by phylogenetic proximity. We examine the effects of including 
only systematic drift (model 6; Table 1) and systematic drift plus phylogenetic diffusion (model 7; Table 1), 
finding a small increase in predictive accuracy of between 0.02 and 0.08 log2 HI titers when both processes 
are included. The systematic drift process informs virus and serum locations by dates of isolation and 
Table 1. Average absolute prediction error of log2 HI titer for test data across models and datasets
Test error
Model Data Dimen Location prior
Serum  
potency
Virus  
avidity A/H3N2 A/H1N1 B/Vic B/Yam
1 HI 1D Uninformed Fixed None 1.35 0.94 0.90 1.08
2 HI 2D Uninformed Fixed None 0.91 0.78 0.82 0.90
3 HI 3D Uninformed Fixed None 0.93 0.80 0.85 0.92
4 HI 4D Uninformed Fixed None 0.98 0.84 0.90 0.97
5 HI 5D Uninformed Fixed None 1.04 0.89 0.98 1.04
6 HI/year 2D Drift Fixed None 0.91 0.75 0.77 0.83
7 HI/year/seq 2D Diffusion/Drift Fixed None 0.89 0.74 0.74 0.83
8 HI/year/seq 2D Diffusion/Drift Estimated None 0.77 0.73 0.66 0.75
9 HI/year/seq 2D Diffusion/Drift Fixed Estimated 0.80 0.72 0.69 0.75
10 HI/year/seq 2D Diffusion/Drift Estimated Estimated 0.76 0.71 0.64 0.72
DOI: 10.7554/eLife.01914.003
Figure 1. Pairwise correlations between genetic distance, measured as amino acid mutations or as phylogenetic distance, and antigenic distance for 
influenza A/H3N2, A/H1N1, B/Vic, and B/Yam. The top row shows correlations between number of amino acid mutations in HA1 and average antigenic 
distance between 10,000 random pairs of viruses. The bottom row shows correlations between average phylogenetic distance, measured in terms of 
years, and average antigenic distance between 10,000 random pairs of viruses. Dashed lines show linear model fits, with R2 and slope noted, while solid 
lines show LOESS fits. Antigenic distances derive from model 2 of Table 1.
DOI: 10.7554/eLife.01914.004
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the phylogenetic diffusion process informs virus locations by genetic sequences. Thus, in these models, 
antigenic locations are inferred using both genetic data and HI data and will differ from locations 
inferred from HI data alone. If HI data is rich, then we expect minor differences in antigenic locations 
with the inclusion of genetic data (as may be the case for A/H3N2), while if HI data is spare, then we 
expect genetic data to play a larger role in determining antigenic locations (as may be the case for 
B/Vic and B/Yam).
We further extend the model by estimating serum potencies, rather than fixing serum potencies at 
maximum titers. Serum potencies differ across isolates due to experimental variation in serum extraction 
and processing or due to variation in ferret immune response. Serum potency determines the baseline 
expectation of titer when virus and serum have identical antigenic locations. However, if serum potency 
is fixed to the serum’s maximum titer, this will often not be the case, as the virus giving the maximum titer 
may be antigenically distinct from the serum. Thus, fixing serum potencies will tend to under-estimate 
effect size; we observe a mean effect of 10.42 log2 HI titers for A/H3N2 when fixing serum potencies and 
a mean of 10.94 when estimating serum potencies. We find that estimating serum potencies improves 
test error further (model 8, Table 1), with improvements of between 0.01 and 0.12 log2 HI titers.
Additionally, we include and estimate ‘virus avidity’ in an analogous fashion, which is intended to 
represent differences in overall HI reactivity between viruses. Experimental work has demonstrated 
that influenza variants exist that differ in HA binding activity for cell surface glycan receptors, and that 
these high-avidity variants may arise in the presence of antibody pressure (Hensley et al., 2009). The 
presence of differential virus avidity has been previously shown to distort antigenic maps constructed 
from a model that disregards avidity effects (Li et al., 2013). Here, with virus avidities estimated, base-
line titer derives from both the virus and the serum used in the HI reaction. We find that including virus 
avidities further improves test error, either with fixed serum potencies (model 9, Table 1) or with esti-
mated serum potencies (model 10, Table 1). With fixed serum potencies, the inclusion of virus avidities 
results in improvements of between 0.02 and 0.09 log2 HI titers and with estimated serum potencies, 
the inclusion of virus avidities results in improvements of between 0.01 and 0.05 log2 HI titers.
We find that the average absolute error in predicted log2 HI titer is nearly constant with antigenic 
distance (Pearson correlation, r = 0.098), thus supporting our model assumption that the drop in log2 
titer is proportional to the Euclidean distance separating viruses and sera on the antigenic map. 
Additionally, we find that the absolute error in predicted titer is nearly constant with time (Pearson 
correlation, r = −0.007). Antigenic locations inferred by the model are well resolved; estimates of 
antigenic distance between pairs of viruses show relatively little variation across the posterior. 
We estimate that virus distances have, on average, a 50% credible interval of ±0.45 antigenic units for 
A/H3N2, ±0.57 units for A/H1N1, ±0.76 units for B/Vic, and ±0.65 units for B/Yam.
We find strong correspondence between our results and previous results by Smith et al. (2004), 
with equivalent models producing globally consistent antigenic maps and other models producing 
locally consistent maps with a small degree of global inconsistency (see ‘Methods’). When implementing 
the same underlying model, differences in the MDS and BMDS approaches reflect greater philosophical 
differences between maximum-likelihood and Bayesian statistical approaches, with the former seeking 
the single most likely explanation for the data, and the latter seeking to fully characterize model 
uncertainty. Additionally, the BMDS method improves flexibility, allowing extensions to the basic 
cartographic model, such as the incorporation of virus avidities and evolutionary priors, that improve 
fit and add biological interpretability.
Antigenic evolution across influenza lineages
Through our analysis, we reveal the antigenic, as well as evolutionary, relationships among viruses in 
influenza A/H3N2, A/H1N1, B/Vic and B/Yam, quantifying both antigenic and evolutionary distances 
between strains (Figure 2, Figure 2—source data 1). Over the time period of 1968 to 2011, influenza 
A/H3N2 shows substantially more antigenic evolution than is exhibited by A/H1N1 over the course of 
1977 to 2009 or B/Vic and B/Yam over the course of 1986 to 2011. We observe prominent antigenic 
clusters in A/H3N2 and A/H1N1, but less prominent, though still apparent, clustering in B/Vic and B/Yam. 
Antigenic clusters show high genetic similarity, so that we observe very few mutation events leading 
to each cluster, rather than the repeated emergence of clusters. This analysis makes the fate of 
antigenic clusters obvious, with two clusters in A/H3N2 (Victoria/75 and Beijing/89) appearing to be 
evolutionary dead-ends. Labeling of prominent antigenic clusters in Figure 2 is intended as a rough 
guide for orientation and not as exhaustive catalog of antigenic variation.
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HI assays lack sensitivity beyond a certain point, so that for A/H3N2, cross-reactive measurements 
only exist between strains sampled at most 14 years apart, leaving only threshold titers, for example 
‘<40’, in more temporally distant comparisons. Because of the threshold of sensitivity of the HI assay, 
it is difficult to distinguish a linear trajectory in 2D antigenic space from a slightly curved trajectory (see 
‘Materials and Methods’). To solve this problem of identifiability, we assumed a weak prior that favors 
linear movement in the 2D antigenic space (present in models 6 through 9; Table 1), with the slope of 
the linear relationship and the precision of the relationship incorporated into the Bayesian model (see 
‘Materials and methods’). Because of this, we interpret map locations locally rather than globally, and 
assess rates of antigenic movement without making strong statements about the larger configuration 
under which the movement occurs.
We find that influenza A/H3N2 evolved along antigenic dimension 1 at an estimated rate of 1.01 
antigenic units per year (Figure 3, Figure 3—source data 1; Table 2). However, we observe occasional 
large jumps in antigenic phenotype (Figure 3), corresponding to cluster transitions identified by Smith 
et al. (2004). Most variation is contained within the first antigenic dimension, but dimension 2 occasionally 
shows variation when two antigenically distinct lineages emerge and transiently coexist (Figure 2), as is 
the case with the previously identified Beijing/89 and Beijing/92 clusters.
We find that other lineages of influenza evolved in antigenic phenotype substantially slower than 
A/H3N2 (Figure 3, Table 2). Influenza A/H1N1 evolved at a rate of 0.62 units per year, but showed a 
similar pattern of punctuated antigenic evolution with occasional larger jumps in phenotype, such as 
the emergence of the Solomon Islands/06 cluster. Influenza B/Victoria and B/Yamagata evolved slower 
still, with mean estimated rates 0.42 units per year and 0.32 units per year, respectively. Punctuated 
evolution is less obvious in B/Yam and B/Vic compared to A/H3N2 and A/H1N1, but antigenic clusters 
are still apparent, with recent transitions to the Brisbane/08 cluster in B/Vic (Barr et al., 2010) and to 
the Wisconsin/10 cluster in B/Yam (Klimov et al., 2012). Interestingly, a minor lineage of B/Vic, 
denoted B/Hubei-Songzi/51/2008 (Barr et al., 2010), has persisted through 2011, while remaining 
antigenically distinct from B/Brisbane/60/2008 viruses (Figure 3). Although we observe significantly 
different drift rates between lineages, we observe less variation in diffusion volatility (Table 2). This is 
Figure 2. Antigenic locations of A/H3N2, A/H1N1, B/Vic, and B/Yam viruses showing evolutionary relationships 
between virus samples. Circles represent a posterior sample of virus locations and have been shaded based on 
year of isolation. Antigenic units represent twofold dilutions of the HI assay. Absolute positioning of lineages, for 
example A/H3N2 and A/H1N1, is arbitrary. Lines represent mean posterior diffusion paths when virus locations are 
fixed. Prominent antigenic clusters are labeled after vaccine strains present within clusters, and are abbreviated 
from Hong Kong/68, England/72, Victoria/75, Bangkok/79, Sichuan/87, Beijing/89, Beijing/92, Wuhan/95, 
Sydney/97, Fujian/02, California/04, Wisconsin/05, Brisbane/07, Perth/09 (A/H3N2), USSR/77, Singapore/86, 
Beijing/95, New Caledonia/99, Solomon Islands/06 (H1N1), Victoria/87, Hong Kong/01, Malaysia/04, Brisbane/08 
(Vic), Yamagata/88, Shanghai/02, Florida/06, Wisconsin/10 (Yam).
DOI: 10.7554/eLife.01914.005
The following source data are available for figure 2:
Source data 1. This tab-delimited text file lists every virus in Figures 2 and 3, including lineage, strain name, year 
of isolation, and coordinates in antigenic dimensions 1 and 2. 
DOI: 10.7554/eLife.01914.006
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reflected in Figure 3, where all four lineages exhibit similar levels of standing antigenic variation, 
despite A/H3N2 drifting more quickly in antigenic phenotype.
These patterns of antigenic drift influence the corresponding virus phylogenies (Figure 4). Influenza 
A/H3N2 has a characteristically spindly tree showing rapid turnover of the virus population, while 
A/H1N1 and B have trees that show greater degrees of viral coexistance (Figure 4). The scaled effective 
population size Neτ measures the timescale of coalescence of a phylogeny and quantifies the visual 
Figure 3. Antigenic drift of A/H3N2, A/H1N1, B/Vic and B/Yam viruses showing evolutionary relationships between 
virus samples. Antigenic drift is shown in terms of change of location in the first antigenic dimension through time. 
Circles represent a posterior sample of virus locations and have been shaded based on year of isolation. Antigenic 
units represent twofold dilutions of the HI assay. Relative positioning of lineages, for example A/H3N2 and A/
H1N1, in the vertical axis is arbitrary. Lines represent mean posterior diffusion paths when virus locations are fixed. 
Prominent antigenic clusters are labeled after vaccine strains present within clusters, and are abbreviated from 
Hong Kong/68, England/72, Victoria/75, Bangkok/79, Sichuan/87, Beijing/89, Beijing/92, Wuhan/95, Sydney/97, 
Fujian/02, California/04, Wisconsin/05, Brisbane/07, Perth/09 (A/H3N2), USSR/77, Singapore/86, Beijing/95, New 
Caledonia/99, Solomon Islands/06 (H1N1), Victoria/87, Hong Kong/01, Malaysia/04, Brisbane/08 (Vic), Yamagata/88, 
Shanghai/02, Florida/06, Wisconsin/10 (Yam).
DOI: 10.7554/eLife.01914.007
The following source data are available for figure 3:
Source data 1. This tab-delimited text file lists every virus in Figures 2 and 3, including lineage, strain name, year 
of isolation, and coordinates in antigenic dimensions 1 and 2. 
DOI: 10.7554/eLife.01914.008
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distinction between a ‘spindly’ tree and a ‘bushy’ tree (Bedford et al., 2011). In this case, Ne repre-
sents the number of concurrent infections in a panmictic population with generation interval τ (time 
separating infections up the genealogical tree), so that Neτ is measured in terms of years and gives the 
expected waiting time for two randomly chosen lineages to coalesce in the genealogical tree. We see 
that Neτ broadly correlates with the rate of antigenic drift (Table 2), with A/H3N2 showing fast drift and 
reduced effective population size as expected from basic epidemiological models (Bedford et al., 
2012). Antigenic drift results in the replacement of antigenically primitive lineages by antigenically 
advanced lineages, thereby reducing genealogical diversity.
Thus, we observe a faster rate of antigenic drift in influenza A/H3N2 than in A/H1N1 or either lineage 
of influenza B. Previous work using general epidemiological models has suggested that rates of anti-
genic drift may be influenced by both the fundamental reproductive number R0 and the rate at which 
Figure 4. Time-resolved phylogenetic trees of A/H3N2, A/H1N1, B/Vic and B/Yam viruses. The maximium-clade 
credibility (MCC) tree is shown for each virus. These trees show genealogical relationships, so that branches are 
measured in terms of years rather than substitutions.
DOI: 10.7554/eLife.01914.010
Table 2. Estimates of drift rate μ (in units per year), diffusion volatility σ2x  (in units2 per year) and 
scaled effective population size Neτ  (in years) for influenza A/H3N2, A/H1N1, B/Vic and B/Yam 
including posterior means and 95% highest posterior density intervals
Lineage Drift μ Volatility 2
x
σ Effective pop size 
e
N τ
A/H3N2 1.01 (0.98–1.04) 1.25 (0.98–2.35) 5.03 (4.42–5.73)
A/H1N1 0.62 (0.56–0.67) 0.92 (0.65–1.56) 6.38 (4.99–8.12)
B/Vic 0.42 (0.32–0.51) 1.22 (0.85–2.25) 10.40 (8.42–12.80)
B/Yam 0.32 (0.25–0.39) 0.71 (0.46–1.36) 9.48 (7.76–11.50)
DOI: 10.7554/eLife.01914.009
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mutation decreases cross-immunity (Gog and Grenfell, 2002; Lin et al., 2003). Correspondingly, 
models specific to influenza evolution ascribe differences in the rate of antigenic drift of A/H3N2 rela-
tive to A/H1N1 and influenza B to either greater R0 or greater mutation rate (Ferguson et al., 2003; 
Bedford et al., 2012). Without more detailed epidemiological modeling, the present study cannot 
conclusively distinguish between these causal possibilities.
Punctuated evolution and its epidemiological consequences
We sought to summarize year-to-year patterns of antigenic drift by calculating the difference in mean 
virus location between consecutive years (Figure 5A). We estimate year-to-year antigenic drift for 
years 1992 to 2011 by calculating the average location along dimension 1 of phylogenetic lineages 
present in the tree at year i and comparing this location to the average location of phylogenetic line-
ages present in the tree at year i − 1. There may often be large discontinuities in virus locations across 
the population; our use of difference in mean location is meant to capture both the distance between 
antigenic clusters and also the change in cluster frequency over consecutive years. We observe greater 
heterogeneity in year-to-year antigenic drift in type A than in type B lineages (Figure 5B), with standard 
deviation of year-to-year antigenic drift equal to 0.97 units in A/H3N2, 0.66 units in A/H1N1, 0.46 units in 
B/Vic and 0.26 units in B/Yam. This analysis classifies drift only to the level of consecutive years; some 
coarse-graining of the timings of transition events will necessarily occur.
We investigate the relationship between rates of antigenic drift and seasonal incidence in the USA 
in A/H3N2, A/H1N1, B/Vic and B/Yam. We measure seasonal incidence from USA CDC influenza 
surveillance reports for each virus lineage (A/H3N2, A/H1N1, B/Vic, B/Yam) by taking the average 
influenza-like (ILI) percentage in a season and multiplying this by the relative proportion of virus 
Figure 5. Year-to-year antigenic drift between 1992 and 2011 in A/H3N2, A/H1N1, B/Vic and B/Yam viruses. 
(A) Timeseries of year-to-year antigenic drift between 1992 and 2011 in A/H3N2, A/H1N1, B/Vic and B/Yam viruses. 
Colored lines represent year-to-year antigenic drift, where drift for year i is measured as the mean of antigenic 
dimension 1 of phylogenetic lineages in year i compared to the mean of antigenic dimension 1 of phylogenetic 
lineages from the previous year i − 1. For example, 2000 represents difference in antigenic dimension 1 between 
viruses from 1999 to 2000. Error bars represent 50% Bayesian credible intervals of year-to-year drift. Gray dotted lines 
represent lineage-specific seasonal incidence in the USA taken as average influenza-like illness (ILI) multiplied by 
proportion of viruses attributable to a lineage for each season. Here, 2000 represents the 2000/2001 influenza season. 
(B) Distribution of year-to-year antigenic drift between 1992 and 2011 in A/H3N2, A/H1N1, B/Vic and B/Yam viruses.
DOI: 10.7554/eLife.01914.011
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isolations attributable to a particular influenza lineage in a season (see ‘Materials and methods’). This 
measure of incidence has previously been shown to have have predictive power in the analysis of 
seasonal influenza trends (Goldstein et al., 2011). We analyze incidence from the 1998/1999 to the 
2008/2009 seasons to avoid possible complications from the 2009 pandemic. We begin by comparing 
overall rates of antigenic drift (Figure 3, Table 2) to overall levels of seasonal incidence across influ-
enza lineages, finding a significant correlation between rate of antigenic drift and relative incidence 
across the four lineages (Pearson correlation, r = 0.97, p = 0.041).
We follow-up this analysis with a more detailed analysis of year-to-year variation in antigenic drift 
and lineage-specific incidence, comparing incidence in a season to antigenic drift of viruses coming 
into this season (Figure 5A). For example, we compare antigenic drift of viruses from 2000 to 2001 to 
incidence in the 2001/2002 season. Within each virus lineage, we find that years with pronounced 
antigenic drift tend to show increased incidence (Figure 6), finding Pearson correlation coefficients 
of 0.51, 0.29, 0.44 and 0.14 for A/H3N2, A/H1N1, B/Vic and B/Yam respectively. We calculated 
significance using bootstrap permutation tests finding p-values of 0.056, 0.201, 0.097, and 0.341 
respectively. We applied a similar bootstrap permutation test to calculate the significance of 
finding the observed degree of correlation across all four lineages, arriving at a p-value of 0.018. 
The fact that we observe periods of pronounced antigenic drift preceding increased incidence in 
each of the four influenza lineages suggests a causal relationship, in which antigenic evolution 
drives increased incidence.
However, it is possible that if sampling count influences cartographic estimates then a spurious 
correlation could arise in which years with greater incidence have higher sample counts and artifactu-
ally high estimates of drift. We controlled for this possibility by testing to see if viral isolate count 
influences estimates of year-to-year drift by correlating drift between years i and i − 1 against the ratio 
of the number of isolates from year i to the number of isolates from year i − 1. We found little correla-
tion when combining data across lineages (Figure 7, Pearson’s r = −0.01). We tested significance fol-
lowing the same bootstrap procedure we used to assess the correlation between drift and incidence, 
finding a p-value of 0.514. Separating lineages gave p-values of 0.717, 0.246, 0.337, 0.504 for A/H3N2, 
A/H1N1, B/Vic and B/Yam, respectively. These findings suggest our results to be unbiased with regard 
to sample count.
Figure 6. Relationship between antigenic drift and seasonal incidence for years 1998 to 2009 in influenza A/H3N2, 
A/H1N1, B/Vic and B/Yam. Antigenic drift from year i − 1 to year i is compared to incidence in the season i/i + 1. For 
example, year-to-year antigenic drift from 2000 to 2001 is measured against incidence in the 2001/2002 season.
DOI: 10.7554/eLife.01914.012
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Conclusions
Understanding antigenic evolution in seasonal 
influenza is crucial to our efforts of surveillance and 
control. Cartographic methods allow complex HI 
datasets to be compressed to more approachable 
location-based summaries that quantify antigenic 
relationships between strains, including relation-
ships not directly measured via HI. In this study, we 
provide a foundation for evolutionary antigenic 
cartography, which seeks to simultaneously assess 
antigenic phenotype and antigenic evolution. We 
use this approach to characterize competitive 
dynamics across influenza lineages A/H3N2, 
A/H1N1, B/Vic and B/Yam and show that antigenic 
evolution within each lineage drives strain replace-
ment and contributes to seasonal incidence 
patterns. We find that influenza A/H3N2 evolves 
faster in antigenic phenotype than A/H1N1, 
which in turn evolves faster than B/Vic or B/Yam. 
Consequently, the influenza A/H3N2 virus popula-
tion turns over more quickly than A/H1N1 or influ-
enza B, exhibiting a smaller effective population 
size and a ‘spindlier’ phylogenetic tree. Furthermore, 
we observe a correlation between antigenic drift 
and viral incidence both across and within influenza lineages. The finding that antigenic evolution correlates 
with subsequent increased incidence within a lineage suggests a causal role for antigenic drift driving influ-
enza incidence patterns. The correlation between incidence and drift further suggests the possibility of 
using HI data at the start of an influenza season to predict which lineage will subsequently predominate.
The statistical framework presented here represents a baseline to which further advancements in 
modeling antigenic phenotype and evolution may be made. For example, our likelihood-based model 
facilitates the inclusion of possible covariates affecting immunological titer, which could include exper-
imental factors such as red blood cell type used in the HI assay (Lin et al., 2012) and whether oseltamivir 
is included in the HI reaction (Lin et al., 2010). Additionally, this framework should be ideally suited 
to uncovering genetic determinants of antigenic change, as both the sequence state and antigenic 
location of internal nodes in the phylogeny may be estimated. In this fashion, it should be possible to 
correlate sequence substitutions directly to antigenic diffusion. Identifying viruses that will come to 
predominate in the global virus population while they are still at low frequency remains an enormous 
challenge. However, combining evolutionary and antigenic information may eventually prove useful in 
identifying low-frequency, but expanding, lineages of antigenically novel viruses that represent ideal 
targets for vaccine strain selection.
Materials and methods
Antigenic cartography
Antigenic characteristics of viral strains are often assessed through immunological assays such as the 
hemagglutination inhibition (HI) assay (Hirst, 1943). At heart, these assays compare the reactivity of one 
virus strain to antibodies raised against another virus strain via challenge or vaccination. In the case of HI, 
the measurement of cross-reactivity takes the form of a titer representing the dilution factor at which 
serum raised against a particular virus ceases to be effective at inhibiting the binding of another virus to 
red blood cells. These factors are commonly assessed by serial dilution, so that HI titers will form a log 
series, 40, 80, 160, etc…. Because experimental HI titers typically differ by factors of two, we find it 
convenient to work in log2 space and represent the titer of virus i against serum j as ijH 2= log (HI titer), 
that is a titer of 160 has Hij = 7.32. Due to experimental constraints, most comparisons cannot be made, 
leading to a sparse observation matrix { }ijH=H . Further, measurements are usually interval and trun-
cated, for example inhibition may cease somewhere between the serial titers of 160 and 320, or inhi-
bition may be absent at all titers assayed, suggesting a threshold somewhere between 0 and 40.
Figure 7. Relationship between antigenic drift and sample 
counts for years 1998 to 2011 in influenza A/H3N2,  
A/H1N1, B/Vic and B/Yam. Antigenic drift from year i − 1 
to year i is compared to the ratio of sample counts in 
year i to counts in year i − 1. Only comparisons which had 
one or more samples in years i − 1 and i were retained, 
leaving 11 A/H3N2, 7 A/H1N1, 9 B/Vic and 10 B/Yam 
comparisons. Points are colored according to influenza 
lineage based on the color scheme in Figure 6.
DOI: 10.7554/eLife.01914.013
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Previous work (Smith et al., 2004; Cai et al., 2010) has used multidimensional scaling (MDS) to place 
viruses and sera on an ‘antigenic map’. These methods heuristically optimize locations of viruses and sera 
by seeking to minimize the sum of squared errors between titers predicted by map locations and observed 
titers. Antigenic maps produced by these methods have proven useful in categorizing virus phenotypes 
(Smith et al., 2004), but the extension of these methods to integrate genetic data remains notably lacking.
Here, we follow previous models in representing antigenic locations as points in a low P-dimensional 
antigenic map. One of our initial goals is to find an optimal projection of the high-dimensional distance 
matrix H into this lower dimensional space. We conduct this projection using Bayesian multidimen-
sional scaling (BMDS) (Oh and Raftery, 2001) in which we construct a probabilistic model to quantify 
the fit of a particular configuration of cartographic locations to the observed matrix of serological 
measurements. Typically, P = 2, but higher or lower dimensions may better reflect the data.
Let RP
i
∈x  represent the cartographic location of virus i for i = 1,…, n, so that ( )i i ix x1 2= , ′x  for P = 
2. Similarly, let yj represent the cartographic location of serum j for j = 1,…, k, so that ( )j j jy y1 2= , ′y  for 
P = 2. For notational compactness, we collect together all virus coordinates into an n × P matrix 
( )1= ,…, n ′X x x  and all serum coordinates into an k × P matrix ( )1= ,…, kY y y ′. Virus and serum may be 
isolated from/raised against the same strain and have different cartographic locations, and separate 
serum isolates raised against the same strain may also have different cartographic locations. This gives 
a set of distances between virus and serum cartographic locations.
−δ ij i j 2=|| || ,x y  (1)
where, ⋅ 2|| ||  is an L2 norm.
Traditional approaches to antigenic cartography (Smith et al., 2004) begin by defining immunological 
distance as
−ij j ijd s H= , (2)
where, Hij is the log2 titer of virus i against serum j and serum potency ( )j j njs H H1=max ,…,  is fixed. 
In following multidimensional scaling, these approaches attempt to optimize over unknown X and 
Y such that
( )
( )
I
δ ij ij
i j
d
2
, ∈
−∑  (3)
is minimized, where, ( ){ }I iji j H= , :  is measured . In the case of threshold measurements, this error 
function is modified slightly; see Smith et al. (2004) for further details.
Here, we instead assume a probabilistic interpretation in which an observed titer is normally distributed 
around its cartographic expectation with variance φ2,
( )ϕ−N δij j ijH s 2, .∼  (4)
Consequently, the likelihood of observing an exact titer given the placement of antigenic locations is
( )| ,ij ij jij H sf H φ ϕ
+δ −  =      (5)
where, ( )φ ⋅  represents the standard normal probability density function (PDF). Previous BMDS has 
employed a sampling density truncated to strictly positive quantities since dij are directly observed, 
non-negative quantities. In the antigenic setting, these remain random and can be negative since nei-
ther sj is known nor is Hij observed with much precision.
HI assays sometimes show no inhibition at all measured titrations, for example a measurement can 
be reported as ‘<40’. In this case, the likelihood of observing the threshold measurement follows the 
cumulative density of the lower tail of the normal distribution.
( ) ϕ
+
= ,
ij ij j
ij
H s
f H┘ Φ
δ −       (6)
where, Φ ⋅( ) represents the standard normal cumulative distribution function (CDF). Although it is sim-
plest to assume that immunological measurements represent point estimates, it seems more natural to 
assume that the threshold for inhibition occurs between two titers, for example we observe inhibition at 
1:160 dilution and no inhibition at 1:320 dilution. Rather than taking the HI titer as 160, we can instead 
treat this as an interval measurement, assuming that the exact titer for inhibition would occur somewhere 
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between 160 and 320. HI titers are usually reported as the highest titer that successfully inhibits virus 
binding, so that in this case, we calculate the likelihood of an interval measurement as
( )    − −   = −        ⊔ ϕ ϕ
ij ij j ij ij j
ij
H s H s
f H Φ Φ+ +1 + .δ δ  (7)
These likelihoods are illustrated in Figure 8. Throughout our analyses, we use interval likelihoods 
⊔f  rather than point likelihoods f|  unless otherwise noted.
We calculate the overall likelihood by multiplying probabilities of individual measurements
( )
( )
( )∏
I
ij
i j
L H
,
, = ,
∈
fX Y  (8)
using probability functions f| , f  and ⊔f  as appropriate. We begin by assuming independent, diffuse 
normal priors on virus and serum locations.
( )N
i
~ ,∑x m
( )Nj ~ , ,∑y m  
(9)
where, ( )= 0,…,0m ′ and ∑ is a diagonal matrix with diagonal elements all equal to 10,000.
Virus avidity and serum potency
The preceding model represents immunological distance as a drop in titer against the most reactive 
comparison for a particular serum. However, this model may be biased in some circumstances. In one 
example, if a particular serum j is only measured against distant viruses, its maximum titer will be arti-
ficially low and the likelihoods concerning this serum will appear poor. To address this issue, we relax 
the assumption of fixed sj values and treat the expected log2 titer when δ ij =0 as a random variable. In this 
case, Hij still follows Equation 4 with expectation −δj ijs , but the vector of ‘serum potencies’ s = (s1,…, sk) 
is random and estimated rather than fixed. We assume that sj values are hierarchically distributed 
according to a normal distribution. We take an Empirical Bayesian approach in specifying the mean 
Figure 8. Likelihood of HI titers in the BMDS model. Here, we show the likelihoods of observing three different 
outcomes given δ ij = 4, ϕ = 0.95, and ( )js 2= log 1280 =10.32. The likelihood of observing a threshold titer of 
‘<40’ is equal to the lower tail of the probability density function ( )f 5.32 = 0.146. The likelihood of observing a 
point measurement with an exact inhibiting titer of ‘90.5’ is equal to the density function ( )f| 6.5 = 0.413. The 
likelihood of observing an interval measurement with an inhibiting titer somewhere between ‘160’ and ‘320’ is 
equal to ( )⊔f 7.32 = 0.129.
DOI: 10.7554/eLife.01914.014
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and variance of this distribution, set to the empirical mean and empirical variance of the set of maximum 
titers across sera ( ){ }j njH H j k1max ,…, : =1,…, . This formulation assumes that particular sera are more 
reactive in general than other sera.
Additionally, we follow the same logic and assume that some virus isolates are more reactive than 
other virus isolates and include a parameter for ‘virus avidity’ vi representing the general level of reac-
tivity across HI assays. With virus avidity included, observed titers follow
  −   
N i jij ij
v s
H ∼ 2+ , ,
2
δ ϕ  (10)
and the vector of virus avidities vi for i = 1,…, n is estimated in an analogous hierarchical fashion, with 
v normally distributed with mean and variance equal to the empirical mean and variance of the set of 
maximum titers across viruses ( ){ }i ikH H i n1max ,…, : =1,…, .
Drift model of antigenic evolution
As presented, multiple configurations of virus and serum locations X and Y will give the same 
likelihood of an observed data matrix H. An example of this phenomenon is shown in Figure 9. In 
this case, it is impossible to determine from the HI data at hand whether the blue and yellow 
viruses are antigenically similar (Figure 9A) or antigenically divergent (Figure 9B). This presents 
an issue of model identifiability, where absolute, as opposed to relative, antigenic locations cannot 
be determined from observing the serological data alone. Thus, in order to achieve a more inter-
pretable model we impose a weak prior on global locations. In influenza, it’s clear that antigenic 
distance between strains increases with time (Smith et al., 2004; Cai et al., 2010). To capture this, 
we replace our previous diffuse prior with an informed prior in which the expected location of 
viruses and sera increases with date of sampling along dimension one, and each virus and serum 
location follows an independent normal distribution centered around this temporal expectation, 
so that
( )∼ Nμ σi i xx t 21 + 0,
( )∼ Ny μj jt 21 y+ 0, ,σ  (11)
where, t is the difference between the date of the indexed virus or serum and the date of the earliest 
sampled virus or serum, and other dimensions follow ( )N σim xx 2~ 0,  and ( )N σjm yy 2~ 0,  for m ≥ 2. Thus, 
Figure 9. Schematic antigenic map with three viruses and two sera. (A) Map with virus 1 and virus 3 antigenically similar. (B) Map with virus 1 and virus 3 
antigenically divergent. Virus 1 is shown in blue, virus 2 is shown in red and virus 3 is shown in yellow. Virus isolates are represented by filled circles, sera 
raised against viruses are shown as open circles and map distances ijδ  are shown as solid lines connecting viruses and sera. Sera from virus 1 is compared 
against viruses 1 and 2, while sera from virus 2 is compared against viruses 2 and 3. Configurations (A) and (B) represent cartographic models that would 
give equal likelihoods to a set of serological data { }H H H H11 21 22 32, , , .
DOI: 10.7554/eLife.01914.015
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this model assumes that virus and serum locations drift in a line across the antigenic map at rate μ. 
The parameter xσ  determines the breadth of the cloud of virus locations at each point in time, while σ
y
 determines the breadth of the cloud of serum locations.
Phylogenetic diffusion model of antigenic evolution
We simultaneously model antigenic locations and genetic relatedness by assuming that virus locations 
are influenced by evolution following a Brownian motion process (Lemey et al., 2010). To do this, we 
replace the previous prior specifying independent virus locations with a prior that incorporates covar-
iance based on shared evolutionary history.
( )
1 0
~ +Evolutionary Brownian Process ,
0
x
n
t
t
        
⋮ ⋮X
μ
σ τ
μ
 (12)
for P = 2, where, σ
x
 is the volatility parameter of the Brownian motion over virus locations and τ is a 
phylogeny specifying tree topology and branch lengths. Thus, viruses that are genetically similar are 
induced to have prior locations close to one another on the antigenic map. In the evolutionary Brownian 
process, the tips of the phylogeny τ correspond to the set of virus locations (x1,…, xn), and the probability 
of observing tip locations depends on the locations of internal nodes (xn+1,…, x2n−2) and on the location 
Figure 10. Comparison of A/H3N2 antigenic locations estimated by Smith et al. (2004) using MDS and an equivalent BMDS model. (A) MDS antigenic 
locations, reoriented so that the primary dimension lies on the x-axis rather than on the y-axis as in Figure 1 of Smith et al. (2004). (B) A posterior 
sample of antigenic locations from an equivalent BMDS model. In (A) and (B), viruses are shown as colored circles, with color denoting antigenic cluster 
inferred by (Smith et al., 2004), and sera are shown as gray points. (C) Antigenic distances between A/Bilthoven/16,190/1968 and all other viruses 
determined for both methods. (D) Antigenic distances between A/Fujian/411/2002 and all other viruses determined for both methods. (E) Antigenic 
distances between 750 random pairs of viruses determined for both methods. In (C), (D) and (E) red points show distances for the MDS model and gray 
bars show the 95% credible interval of distances for the BMDS model, while the red dashed line shows a LOESS regression to MDS distances, and the 
black dashed line shows a LOESS regression to the BMDS distances. The BMDS model has a Uniform (−100, 100) prior on antigenic locations and serum 
potencies fixed at maximum titer values.
DOI: 10.7554/eLife.01914.016
The following source data are available for figure 10:
Source data 1. This tab-delimited text file lists every virus and serum in Figure 10, including strain name, year of isolation, coordinates in antigenic 
dimensions 1 and 2, and potency for sera. 
DOI: 10.7554/eLife.01914.017
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of the root node x2n−2. This process assumes that a virus location xi follows from the location of its 
parent virus xf(i), and with the addition of drift along dimension 1, is distributed as
( ) ( )( ),0 Niμ di if i d,∼ +x x′ ∑  (13)
for P = 2, where, f(i) is a function that maps nodes to parental nodes, di is the length of the branch 
connecting virus i to parent virus f(i), and ∑ is a diagonal matrix with diagonal elements all equal to σ
x
2. 
The root virus location x2n−1 is assumed to follow a normal distribution with expectation ( )
−
μ
n
t
2 1
,0 ′ for 
P = 2 and variance determined by the diffusion volatility σ
x
 (Lemey et al., 2010). The probability of 
virus locations ( )x| , ,p X μ σ τ  is determined through analytical integration across internal states fol-
lowing the methods introduced in (Lemey et al., 2010). This formulation corresponds to a Wiener pro-
cess with drift, in which the drift term μ only influences the expected states of nodes along the phylogeny, 
but does not influence the covariance structure among these nodes, which remains the same as it does 
in a standard Wiener process (Borodin and Salminen, 2002). This allows the separation in Equation 12 
between drift terms affecting only expectations and the evolutionary Brownian process that includes 
covariance among virus locations (x1,…, xn).
Figure 11. Comparison of A/H3N2 antigenic locations estimated by Smith et al. (2004) using MDS and an equivalent BMDS model under an alternative 
solution. (A) MDS antigenic locations, reoriented so that the primary dimension lies on the x-axis rather than on the y-axis as in Figure 1 of Smith et al. 
(2004). (B) A posterior sample of antigenic locations from an equivalent BMDS model that has converged on the alternative solution. In (A) and (B), viruses 
are shown as colored circles, with color denoting antigenic cluster inferred by Smith et al. (2004), and sera are shown as gray points. (C) Antigenic distances 
between A/Bilthoven/16,190/1968 and all other viruses determined for both methods. (D) Antigenic distances between A/Fujian/411/2002 and all other 
viruses determined for both methods. (E) Antigenic distances between 750 random pairs of viruses determined for both methods. In (C), (D) and (E) red 
points show distances for the MDS model and gray bars show the 95% credible interval of distances for the BMDS model, while the red dashed line 
shows a LOESS regression to MDS distances, and the black dashed line shows a LOESS regression to the BMDS distances. The BMDS model has a 
Uniform (−100, 100) prior on antigenic locations and serum potencies fixed at maximum titer values.
DOI: 10.7554/eLife.01914.018
The following source data are available for figure 11:
Source data 1. This tab-delimited text file lists every virus and serum in Figure 11, including strain name, year of isolation, coordinates in antigenic 
dimensions 1 and 2, and potency for sera. 
DOI: 10.7554/eLife.01914.019
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In this study, the phylogenetic tree τ is estimated using sequence data for viruses 1,…, n according 
to well-established methods implemented in the software package BEAST (Drummond et al., 2012).
Posterior inference
Top-level priors for ϕ21/ , μ, σ
x
2
1/ , and σ
y
2
1/  are assumed to follow diffuse Gamma(a, b) distributions 
with a = 0.001 and b = 0.001. These diffuse priors were chosen to be non-informative and provide 
little-to-no weight on the resulting posterior distributions. Under the full model, the posterior proba-
bility of observing virus and serum locations given immunological data is factored.
( ) ( ) ( ) ( ) ( )| | | |ϕ ϕ∝ μ σ τ μ σ μ σ σ τx y x yp p p p p, , , , , , , , , , , , , , .X Y H H X Y s v X Y s v  (14)
We sample from this posterior distribution using the MCMC procedures implemented in the soft-
ware package BEAST (Drummond et al., 2012). Metropolis–Hastings proposals include transition 
kernels that translate individual virus and serum locations xi and yj and individual virus avidities vi and 
serum potencies sj, and other transition kernels that scale the entire set of virus and serum locations X 
and Y and that scale parameters φ, μ, σ
x
 and σ
y
. For the present analysis, a two-step approach was 
taken to sample phylogenies, where a posterior sample of phylogenies was gathered using sequence 
data and then, in the cartographic analysis, trees from this set were randomly proposed and accepted 
following the Metropolis–Hastings algorithm (Pagel et al., 2004).
Figure 12. Comparison of A/H3N2 antigenic locations estimated by Smith et al. (2004) using MDS and an extended BMDS model that includes 
date-informed priors on antigenic locations. (A) MDS antigenic locations, reoriented so that the primary dimension lies on the x-axis rather than on the 
y-axis as in Figure 1 of Smith et al. (2004). (B) A posterior sample of antigenic locations from a BMDS model that includes date-informed priors on 
antigenic locations. In (A) and (B), viruses are shown as colored circles, with color denoting antigenic cluster inferred by Smith et al. (2004), and sera are 
shown as gray points. (C) Antigenic distances between A/Bilthoven/16,190/1968 and all other viruses determined for both methods. (D) Antigenic 
distances between A/Fujian/411/2002 and all other viruses determined for both methods. (E) Antigenic distances between 750 random pairs of viruses 
determined for both methods. In (C), (D) and (E) red points show distances for the MDS model and gray bars show the 95% credible interval of distances 
for the BMDS model, while the red dashed line shows a LOESS regression to MDS distances, and the black dashed line shows a LOESS regression to the 
BMDS distances. The BMDS model has a date-informed prior on antigenic locations and serum potencies fixed at maximum titer values.
DOI: 10.7554/eLife.01914.020
The following source data are available for figure 12:
Source data 1. This tab-delimited text file lists every virus and serum in Figure 12, including strain name, year of isolation, coordinates in antigenic 
dimensions 1 and 2, and potency for sera. 
DOI: 10.7554/eLife.01914.021
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Genetic, antigenic and surveillance data
We compiled an antigenic dataset of hemagglutination inhibition (HI) measurements of virus isolates 
against post-infection ferret sera for influenza A/H3N2 by collecting data from previous publications 
(Hay and Gregory, 2001; Smith et al., 2004; Russell et al., 2008; Barr et al., 2010), NIMR vaccine 
strain selection reports for 2002 and 2008–2012 (Hay et al., 2002; 2008a, 2009a; McCauley et al., 
2010a; 2010b, 2011b, 2012) and the February 2011 VRBPAC report (Cox, 2011). We queried the 
Influenza Research Database (Squires et al., 2012) and the EpiFlu Database (Bogner et al., 2006) for 
HA nucleotide sequences by matching strain names, for example A/HongKong/1/1968, and only 
strains for which sequence was present were retained. If a strain had multiple sequences in the data-
bases, we preferentially kept the IRD sequence and preferentially kept the longest sequence in IRD. 
Many strains had full length HA sequences, while other strains only possessed HA1 sequences. 
Sequences were aligned using MUSCLE v3.7 under default parameters (Edgar, 2004). This dataset 
had 2051 influenza isolates (present as either virus or serum in HI comparisons) dating from 1968 to 
2011. However, the majority of isolates were present from 2002 to 2007. Because we are interested in 
longer-term antigenic evolution, we subsampled the data to have at most 20 virus isolates per year, 
preferentially keeping those isolates with more antigenic comparisons. We then kept only those serum 
isolates that are relatively informative to the antigenic placement of viruses, dropping serum isolates 
that are compared to four or fewer different virus isolates. This censoring left 402 virus isolates, 519 serum 
Figure 13. Comparison of A/H3N2 antigenic locations estimated by Smith et al. (2004) using MDS and an extended BMDS model that estimates 
serum and virus avidities. (A) MDS antigenic locations, reoriented so that the primary dimension lies on the x-axis rather than on the y-axis as in Figure 1 
of Smith et al. (2004). (B) A posterior sample of antigenic locations from a BMDS model that estimates virus avidity and serum potency. In (A) and (B), 
viruses are shown as colored circles, with color denoting antigenic cluster inferred by Smith et al. (2004), and sera are shown as gray points. 
(C) Antigenic distances between A/Bilthoven/16,190/1968 and all other viruses determined for both methods. (D) Antigenic distances between A/
Fujian/411/2002 and all other viruses determined for both methods. (E) Antigenic distances between 750 random pairs of viruses determined for both 
methods. In (C), (D), and (E) red points show distances for the MDS model and gray bars show the 95% credible interval of distances for the BMDS 
model, while the red dashed line shows a LOESS regression to MDS distances, and the black dashed line shows a LOESS regression to the BMDS 
distances. The BMDS model has a Uniform (−100, 100) prior on antigenic locations and virus avidities and serum potencies estimated in a hierarchical 
Bayesian fashion.
DOI: 10.7554/eLife.01914.022
The following source data are available for figure 13:
Source data 1. This tab-delimited text file lists every virus and serum in Figure 13, including strain name, year of isolation, coordinates in antigenic 
dimensions 1 and 2, potency for sera and avidity for viruses. 
DOI: 10.7554/eLife.01914.023
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isolates and 10,059 HI measurements. Each virus isolate was compared to an average of 21.9 serum 
isolates, and each serum isolate was compared to an average of 18.0 virus isolates.
Antigenic data for influenza A/H1N1 was collected from previous publications (Kendal et al., 1978; 
Nakajima et al., 1979; Webster et al., 1979; Nakajima et al., 1981; Chakraverty et al., 1982; Pereira 
and Chakraverty, 1982; Cox et al., 1983; Daniels et al., 1985; Chakraverty et al., 1986; Raymond 
et al., 1986; Stevens et al., 1987; Donatelli et al., 1993; Hay and Gregory, 2001; Daum et al., 
2002; McDonald et al., 2007; Barr et al., 2010) and NIMR vaccine strain selection reports for 2002–2010 
(Hay et al., 2002, 2008a, 2009a; McCauley et al., 2010; Hay et al., 2003, 2004, 2005a, 2005b, 
2006a, 2006b, 2007a, 2007b, 2008b). The same procedure that was followed for A/H3N2 was repeated 
to match sequence data and to subsample antigenic comparisons. This procedure yielded 115 virus 
isolates, 77 serum isolates, and 1882 HI measurements over the course of 1977–2009. Each virus isolate 
was compared to an average of 10.0 serum isolates, and each serum isolate was compared to an average 
of 16.2 virus isolates.
Antigenic comparisons for influenza B/Victoria were collated from previous publications (Rota 
et al., 1990; Hay and Gregory, 2001; Muyanga et al., 2001; Shaw et al., 2002; Ansaldi et al., 2004; 
Puzelli et al., 2004; Xu et al., 2004; Barr et al., 2006; Daum et al., 2006; Lin et al., 2007) and vaccine 
strain selection reports for 2002–2012 (Hay et al., 2002, 2008a, 2009a; McCauley et al., 2010a; 
2010b, 2011b, 2012; Hay et al., 2003, 2004, 2005a, 2005b, 2006a, 2006b, 2007a, 2007b; Gust 
et al., 2006; Hay et al., 2009a; McCauley et al., 2011b). Here, the sequence matching and subsampling 
procedure yielded 179 virus isolates, 70 serum isolates and 2003 HI measurements over the course of 
1986–2011. Each virus isolate was compared to an average of 6.5 serum isolates, and each serum 
isolate was compared to an average of 16.7 virus isolates.
Antigenic comparisons for influenza B/Yamagata were collected from previous publications 
(Kanegae et al., 1990; Rota et al., 1990; Nakajima et al., 1992; Nerome et al., 1998; Hay and 
Gregory, 2001; Muyanga et al., 2001; Nakagawa et al., 2002; Shaw et al., 2002; Abed et al., 2003; 
Ansaldi et al., 2003, 2004; Matsuzaki et al., 2004; Puzelli et al., 2004; Xu et al., 2004; Barr et al., 
2006; Daum et al., 2006; Lin et al., 2007) and vaccine strain selection reports for 2002–2012 (Hay 
et al., 2002, 2008a, 2009a; McCauley et al., 2010a; 2010b, 2011b, 2012; Hay et al., 2003, 2004, 
2005a, 2005b, 2006a, 2006b, 2007a, 2007b; Gust et al., 2006; Hay et al., 2009a; McCauley et al., 
2011b). For B/Yamagata, the matching and subsampling procedure resulted in 174 virus isolates, 69 
serum isolates and 1962 HI measurements over the course of 1987–2011. Each virus isolate was com-
pared to an average of 6.9 serum isolates, and each serum isolate was compared to an average of 17.3 
virus isolates.
Surveillance data was obtained from the Centers of Disease Control and Prevention FluView 
Influenza Reports from the yearly summaries of influenza seasons 1997–1998 to 2010–2011 (Centers 
for Disease Control and Prevention, 2012). As an example, one report states ‘collaborating labora-
tories in the United States tested 195,744 respiratory specimens for influenza viruses, 27,682 (14%) of 
which were positive. Of these, 18,175 (66%) were positive for influenza A viruses, and 9507 (34%) were 
positive for influenza B viruses. Of the 18,175 specimens positive for influenza A viruses, 7631 (42%) 
were subtyped; 6762 (87%) of these were seasonal influenza A (H1N1) viruses, and 869 (13%) were 
influenza A (H3N2) viruses’. In this case, we estimate the relative proportion of A/H3N2 of the four 
lineages as 0.66 × 0.13 = 0.09. Similar calculations were performed for A/H1N1, B/Vic and B/Yam.
Implementation
Phylogenetic trees were estimated for A/H3N2, A/H1N1, B/Vic, and B/Yam using BEAST (Drummond 
et al., 2012) and incorporated the SRD06 nucleotide substitution model (Shapiro et al., 2006), a co-
alescent demographic model with constant effective population size and a strict molecular clock across 
branches. MCMC was run for 60 million steps and trees were sampled every 50,000 steps after allow-
ing a burn-in of 10 million steps, yielding a total sample of 2000 trees. These trees were treated as a 
discrete set of possibilities when subsequently sampled in the BMDS analysis (Pagel et al., 2004). 
However, it would be possible to jointly sample from sequence data and serological data using these 
methods.
MCMC was used to sample virus locations X, serum locations Y, virus avidities v, serum potencies 
s, MDS precision ϕ21/ , antigenic drift rate μ, virus location precision σ
x
2
1/ , serum location precision 
σ
y
2
1/ , and phylogenetic tree τ. MCMC chains were run for 500 million steps and parameter values 
sampled every 200,000 steps after a burn-in of 100 million steps, yielding a total of 2000 MCMC 
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samples. In all cases, when drift parameter μ was included the MCMC chain mixed well and arrived at 
the same estimated posterior distribution from different starting points. However, without drift param-
eter μ, maps for A/H3N2 showed some degree of metastability, where some chains would converge 
on one solution and other chains would converge on a different solution. We favor models that include 
μ, because its inclusion, in addition to correcting most identifiability issues, yields much improved mix-
ing of antigenic locations.
There is some difficulty in summarizing posterior cartographic samples, as sampled virus and serum 
locations represent only relative quantities, and because of this, over the course of the MCMC, virus 
locations may shift. Our prior on virus and serum locations remove much of this issue, orienting the 
antigenic map along dimension 1 and fixing it to begin at the origin. However, local isometries are 
often still a problem. For example, in A/H3N2 the HK/68, EN/72 and VI/75 clusters may rotate in rela-
tion to other clusters. Consequently, it may be difficult to fully align MCMC samples using Procrustes 
analysis. For the present study, we take a simple approach and sample a single MCMC step and visu-
alize the antigenic locations at this state (Figure 2, Figure 3). Then, for specific quantities of interest, 
like rate of antigenic drift and rate of diffusion at different points along the phylogeny, we calculate the 
quantity across MCMC samples to yield an expectation and a credible interval. This approach accu-
rately characterizes uncertainty that may be hidden in an analysis of a single antigenic map.
We summarize diffusion paths of viral lineages (Figure 2, Figure 3) by taking each virus and recon-
structing x and y locations along antigenic dimensions 1 and 2 backward through time. We use MCMC 
to sample tip locations, but when outputting trees sample internal node locations using a peeling 
algorithm as described in Pybus et al. (2012). Thus, after the MCMC is finished, we have a posterior 
sample of 2000 trees each tagged with estimated tip locations and internal node locations. We post-
processed each posterior tree by conducting a linear interpolation between parent–child node loca-
tions to arrive at x and y values at intervals of 0.05 years for each virus. Then, for each interval, x and y 
values are averaged across the sample of posterior trees. We draw lines between these locations to 
approximate mean posterior diffusion paths. As virus lineages coalesce backwards through time down 
the phylogeny these diffusion paths will also coalesce.
Comparison with previous results
Here, we attempt to compare antigenic locations inferred by our BMDS model to antigenic locations 
previously inferred by the error minimization methods of Smith et al. (2004), referred to here as anti-
genic cartography by MDS. For this comparison, we use exactly the same HI data used to produce the 
results in Smith et al. (2004), consisting of 273 virus isolates, 79 serum isolates and a total of 4252 HI 
measurements taken between 1968 and 2003. We begin with a BMDS analog of the antigenic model 
used in Smith et al. (2004), where serum potencies are taken as the maximum titer of a particular 
ferret serum and the expected log2 drop in HI titer is proportional to Euclidean distance between virus 
and serum locations. To bring models into further alignment, we use a Uniform (−100, 100) distribution 
over virus locations and serum locations. Unsurprisingly, we find that this BMDS model produces 
results that are strongly congruent with MDS results (Figure 10, Figure 10—source data 1). Antigenic 
cluster locations are consistent between methods (Figure 10A–B) and antigenic distances between 
pairs of viruses are consistent between temporally similar and temporally divergent viruses (Figure 10C–E), 
suggesting that the resulting maps are consistent at both local and global scales. Credible intervals of 
antigenic distances for the BMDS model remain narrow across the temporal spectrum (Figure 10C–E), 
implying a fair degree of rigidity to the map.
Smith et al. 2004 show that there exist at least two solutions in their assignment of antigenic 
locations, involving the rotation of clusters HK/68, EN/72 and VI/75 (shown in Figure S2 of [Smith 
et al., 2004]). We observe the same metastable behavior in our analysis; some MCMC chains converge 
on the solution shown in Figure 10B, while other MCMC chains converge on the alternative solution 
shown in Figure 11B. The distribution of likelihood values appears highly similar between these two 
solutions, suggesting that they represent global optima. The rotation of the HK/68, EN/72, and 
VI/75 clusters creates a map that bends slightly, so that temporally distant viruses appear closer in 
the rotated solution than in the original solution (Figure 11C–E, Figure 11—source data 1). In this case, 
it is clear that the solutions are locally consistent between viruses up to ∼15 years divergent, even if 
there is some degree of global flexibility. 
As discussed in the main text, the presence of multiple optima with different degrees of 2D curva-
ture implies an issue of identifiability; the HI likelihood model alone cannot distinguish between these 
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possibilities. Because of this issue, and to more easily estimate rates of antigenic drift, we include a 
model of systematic drift in antigenic location that favors linear movement in the antigenic map. We 
find that including this drift prior on antigenic locations removes the problem of identifiability. Antigenic 
locations produced by this model remain locally consistent with MDS results between viruses 
∼15 years divergent, but global comparisons show that this BMDS model has partitioned more 
variance to the first antigenic dimension (Figure 12, Figure 12—source data 1). We additionally find 
that including the drift prior on antigenic locations often results in greater predictive power, with a 
slight improvement of test error for the A/H1N1, B/Vic, and B/Yam datasets (Table 1).
Our final BMDS model (model 9, Table 1) differs from antigenic model used by Smith et al. (2004) in 
including temporally- and phylogenetically-informed priors on antigenic locations and also in estimating 
serum and virus avidities. Here, we investigate the impact on antigenic locations of estimating virus 
avidity and serum potency in the BMDS model. To isolate this difference, we use a Uniform (−100, 100) 
prior on antigenic locations. Surprisingly, estimating virus avidity and serum potency results in a more 
linear antigenic map (Figure 13, Figure 13—source data 1), resembling the appearance of the map 
incorporating the antigenic drift prior, while preserving local consistency. We generally observe congru-
ence between MDS and BMDS antigenic locations for viruses less than ∼10 years divergent (Figure 13E). 
However, specific viruses may be affected, for instance A/Bilthoven/16,190/1968 (Figure 13C), which 
appears more distant from all other viruses when serum and virus avidities are included.
In this dataset, viruses 15 or more years divergent always yield threshold titers, and hence, their 
relative locations must be indirectly inferred rather than through direct comparison. This may explain 
why we observe local consistency between models at scales less than ∼15 years, but some degree of 
global inconsistency. Still, these results suggest that, when making local comparisons, such as those 
used to calculate year-to-year antigenic drift (Figure 3), outcomes are expected to be robust to many 
model particulars.
Availability
Source code implementing the cartographic models has been made fully available as part of the software 
package BEAST (Drummond et al., 2012), and can be downloaded from its Google code repository 
(http://code.google.com/p/beast-mcmc/). More details on implementing these models can be found 
at https://github.com/trvrb/flux/tree/master/example-xmls. Incidence data and HI data used in this 
analysis is archived with Dryad (doi: 10.5061/dryad.rc515).
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